Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Breast Cancer
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

You are being asked to take part in this study because you have inflammatory breast cancer (IBC) or triple negative breast cancer (TNBC) that is metastatic (has spread to other parts of the body). The goal of this clinical research study is to learn if pembrolizumab (also called MK-3475 and Keytruda) can help to control metastatic IBC and TNBC. The safety of this drug will also be studied. This is an investigational study. Pembrolizumab is FDA approved and commercially available for the treatment of metastatic melanoma. Its use in patients with metastatic IBC and TNBC is investigational. The study doctor can describe how the study drug is designed to work. Up to 35 participants will be enrolled in this study. All will take part in at MD Anderson.

Provided treatments

  • Drug: MK-3475
  • Behavioral: Follow Up/Phone Call
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02411656. The sponsor of the trial is M.D. Anderson Cancer Center and it is looking for 35 volunteers for the current phase.
Official trial title:
A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer (IBC) or Non-IBC Triple Negative Breast Cancer (TNBC) Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy